Flu vaccine linked to narcolepsy in under 30s: study

A vaccine used in Sweden in the 2009-2010 "swine flu" pandemic is linked to a higher risk of the sleeping disorder narcolepsy among under 30s, and not just children and teens as previously thought, a Swedish study showed Tuesday.

Risk of narcolepsy was three times higher among those under the age of 20 who were given the Pandemrix vaccine compared with those who were not inoculated, and twice as high in those aged 21 to 30 years, the Medical Products Agency said.

The risk declined gradually with age and was non-existent by the age of 40.

In real terms, the risk of under 20s developing narcolepsy was an extra four cases per 100,000 vaccinated people per year, and for 21-30 year olds, an extra two cases per 100,000, the author of the study, Ingemar Persson, said.

"We're talking about a horribly debilitating disorder, and that's too many cases caused by a vaccine of all things," he said.

Narcolepsy is a of the nervous system that causes excessive drowsiness, often causing people to fall asleep uncontrollably.

It normally occurs among 25-50 of every 100,000 people, although figures are sketchy, according to a recent British study.

Pandemrix, made by British drug company , was given to around 60 percent of the Swedish population during the 2009-2010 .

In Sweden, some 200 children under the age of 19 developed narcolepsy after receiving Pandemrix, while in neighbouring Finland, which also used the same vaccine, some 79 children were diagnosed with the disorder.

Both Finland and Sweden recommended their populations, of around five and 10 million respectively, to take part in mass vaccinations during the swine flu scare. Pandemrix was the only vaccine used in both countries.

Both governments have agreed to provide for the affected children after their own national research showed a link between the and narcolepsy.

Sweden's Pharmaceutical Insurance agency said it would now examine whether to provide compensation to some 90 young adults who have developed narcolepsy.

"The problem came as a total surprise and since it's such a rare disease it wasn't something we could have looked into beforehand," professor Persson said, defending Sweden's mass vaccination programme.

Pandemrix uses an adjuvant, or booster, called AS03, which aims to strengthen the immune response to the H1N1 virus.

More than a fifth of the world's population was infected with the H1N1 virus in the 2009-2010 pandemic, according to estimates published in January.

add to favorites email to friend print save as pdf

Related Stories

Swine flu vaccine likely causes child narcolepsy: study

Feb 01, 2011

Children injected with the Pandemrix swine flu vaccine were nine times more likely to contract narcolepsy than those who were not vaccinated, a preliminary study by Finland's National Institute for Health and Welfare, THL, ...

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

Oct 24, 2014

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments